Aptinyx Inc

Aptinyx stock falls after NYX-2925 trial for treating painful diabetic nerve damage fails to meet endpoint

However, the biotech said it will still conduct an exploratory Phase 2 study of NYX-2925 for treating patients with fibromyalgia or muscle pain

Researchers working in a lab
The Evanston, Illinois-based clinical-stage company develops therapies for disorders of the brain and nervous system

Shares in Aptinyx Inc (NASDAQ:APTX) tumbled Wednesday after the biotech disclosed that the Phase 2 study of its treatment for painful diabetic peripheral neuropathy (DPN), which is nerve damage caused by high blood sugar, did not meet its primary endpoint.

The Evanston, Illinois-based biotech’s therapy, did not show a significant difference in patients' daily pain scores compared to placebo.

“This four-week proof-of-concept study of our novel NMDA receptor modulator, NYX-2925, in painful DPN was designed to evaluate a 20-fold dose range, determine whether efficacy and dose response could be observed on primary and secondary endpoints, and assess safety in a patient population,” said Aptinyx CEO Norbert Riedel. “While the study did not meet its primary endpoint, we observed improvements on multiple measures, differential activity across dose levels, and a very favorable safety profile.”

READ: Valens GroWorks aims to capture a higher-level market in the cannabis extract space

The stock fell more than 73% to $4.78 in afternoon trade.

The company, however, said it is still conducting an exploratory Phase 2 study of NYX-2925 in patients with fibromyalgia or widespread muscle pain and tenderness. It said a full analysis of the data should be available in the first half of 2019.

The clinical-stage company develops therapies for disorders of the brain and nervous system. Allergan plc (NYSE:AGN) recently acquired its depression drug AGN-241751 for further development.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Aptinyx Inc

Price: $3.11

Market: NASDAQ
Market Cap: $104.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Empower Clinics begins trading on the OTCQB under the ticker...

Empower Clinics (CSE: CBDT-OTC: EPWCF) Chairman and CEO Steven McAuley sat down with Steve Darling from Proactive Vancouver to share news the company is now trading in the United States. Empower is now listed on the OTCQB market and McAuley talks about what this means for the company and...

50 minutes ago

2 min read